Paul Lorigan

Paul Lorigan

UNVERIFIED PROFILE

Are you Paul Lorigan?   Register this Author

Register author
Paul Lorigan

Paul Lorigan

Publications by authors named "Paul Lorigan"

Are you Paul Lorigan?   Register this Author

100Publications

10450Reads

33Profile Views

Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.

Eur J Cancer 2019 Jul 15;116:207-215. Epub 2019 Jun 15.

Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.05.015DOI Listing
July 2019

Survival of patients with early invasive melanoma down-staged under the new eighth edition of the American Joint Committee on Cancer staging system.

J Am Acad Dermatol 2019 Jan 16;80(1):272-274. Epub 2018 Apr 16.

Population Health Department, Queensland Institute of Medical Research Berghofer Medical Research Institute, Herston, Australia; Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.04.017DOI Listing
January 2019

Emergency management of immune-related hypophysitis: Collaboration between specialists is essential to achieve optimal outcomes.

Cancer 2018 12 23;124(24):4731. Epub 2018 Oct 23.

Departments of Acute Medicine, Endocrinology and Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31789
Publisher Site
http://dx.doi.org/10.1002/cncr.31789DOI Listing
December 2018

25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial.

Br J Cancer 2018 10 23;119(7):793-800. Epub 2018 Jul 23.

Cambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, CB2 0QQ, Cambridge, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-018-0179-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189120PMC
October 2018

The role of nivolumab in melanoma.

Future Oncol 2018 Jun 12;14(13):1241-1252. Epub 2018 Jan 12.

The Christie NHS Foundation Trust, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0484DOI Listing
June 2018

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

N Engl J Med 2018 May 15;378(19):1789-1801. Epub 2018 Apr 15.

From the Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif (A.M.M.E., C.R.), Hospices Civils de Lyon Cancer Institute, Cancer Research Center of Lyon, Lyon University, Lyon (S.D.), and Aix-Marseille University, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille (J.-J.G.) - all in France; Netherlands Cancer Institute-Antoni van Leeuwenhoek (C.U.B., A.C.J.A.) and VU University Medical Center (A.J.M.E.), Amsterdam, and Radboud University Medical Center Nijmegen, Nijmegen (R.K.) - all in the Netherlands; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo (M. Mandala), Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione G. Pascale, Naples (P.A.A.), and Universita Degli Studi Di Siena-Policlinico le Scotte, Siena (M. Maio) - all in Italy; Melanoma Institute Australia, the University of Sydney, and Mater and Royal North Shore Hospitals (G.V.L.) and Westmead and Blacktown Hospitals, Melanoma Institute Australia and the University of Sydney (M.S.C.), Sydney, Princess Alexandra Hospital, University of Queensland, Brisbane (V.A.), Alfred Hospital (A.H.) and Peter MacCallum Cancer Centre (S. Sandhu), Melbourne, VIC, and Fiona Stanley Hospital-University of Western Australia-Edith Cowan University Perth, Perth (A.K.) - all in Australia; Cancer Research Center, Moscow (M.L.); Royal Marsden Hospital, London (J.L.); Hospital Clinic Universitari de Barcelona, Barcelona (S.P.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); University Hospital Essen, Essen and German Cancer Consortium, Heidelberg (D.S.), and the Skin Cancer Center, Department of Dermatology, Hannover Medical School, Hannover (R.G.) - all in Germany; Washington University School of Medicine, St. Louis (L.H.-A.); Centre Hospitalier de l'Université de Montréal (CHUM), Centre de Recherche du CHUM, Montreal (R.J.); Christie NHS Foundation Trust, Manchester, United Kingdom (P.L.); Merck, Kenilworth, NJ (N.I.); and the European Organization for the Research and Treatment of Cancer Headquarters, Brussels (S.M., S. Suciu).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1802357DOI Listing
May 2018

Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis.

Clin Pharmacol Ther 2018 04 16;103(4):582-590. Epub 2017 Oct 16.

The Christie NHS Foundation Trust, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpt.875DOI Listing
April 2018

Management of Chronic Hypotony Following Bilateral Uveitis in a Patient Treated with Pembrolizumab for Cutaneous Metastatic Melanoma.

Ocul Immunol Inflamm 2019 19;27(6):1012-1015. Epub 2018 Apr 19.

Department of Ophthalmology, Warrington & Holton Hospitals NHS Foundation Trust, Lovely Lane , Warrington , UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09273948.2018.1459733DOI Listing
April 2018

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

J Clin Oncol 2018 02 3;36(4):383-390. Epub 2017 Jul 3.

James Larkin, Royal Marsden NHS Foundation Trust, London; Paul Lorigan, The Christie National Health Service Foundation Trust, Manchester, United Kingdom; David Minor, California Pacific Medical Center Research Institute; Adil Daud, University of California San Francisco, San Francisco; Bartosz Chmielowski, University of California, Santa Monica, CA; Sandra D'Angelo, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College; Jeffrey Weber, Perlmutter Cancer Center at New York University-Langone Medical Center, New York; Nikhil Khushalani, Roswell Park Cancer Institute, Buffalo, NY; Gerald Linette, Washington University, St. Louis, MO; Christopher D. Lao, University of Michigan, Ann Arbor, MI; Kenneth Grossmann, Huntsman Cancer Institute, Salt Lake City, UT; Mario Sznol, Yale Comprehensive Cancer Center, New Haven, CT; Jeffrey Sosman, Northwestern University, Chicago, IL; Dana Walker, George Kong, and Christine Horak, Bristol-Myers Squibb, Princeton, NJ; Bart Neyns, University Hospital, Vrije Universiteit Brussel, Brussels, Belgium; Michael Smylie, Cross Cancer Institute, Edmonton, Alberta; Wilson H. Miller Jr, Jewish General Hospital and Segal Cancer Centre, McGill University, Montreal, Quebc, Canada; Ralf Gutzmer, Medizinische Hochschule Hannover, Hannover; Jessica C. Hassel, Nationale Centrum für Tumorerkrankungen Heidelberg, Heidelberg; Dirk Schadendorf, University Hospital Essen, Essen, Germany; and Christoph Hoeller, Medical University of Vienna, Wien, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.8023DOI Listing
February 2018

Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab.

BMJ Case Rep 2018 Feb 8;2018. Epub 2018 Feb 8.

Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2017-223249DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836669PMC
February 2018

Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy.

J Natl Cancer Inst 2018 01;110(1)

European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Gustave Roussy Cancer Campus Grand Paris, Villejuif, France; The Christie NHS Foundation Trust, Manchester, UK; University of Pittsburgh Cancer Institute and School of Medicine, Pittsburgh, PA; Mayo Clinic Rochester, Rochester, MN; University of Tubingen, Tubingen, Germany; University of Edinburgh, Western General Hospital, Edinburgh, UK; Bristol-Myers Squibb, Wallingford, CT; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK; Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK; Universitas Brawijaya, Malang, Indonesia; IDDI, Louvain-la-Neuve, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djx133DOI Listing
January 2018

Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy.

Am Soc Clin Oncol Educ Book 2017 ;37:651-660

From the University of Pittsburgh, Pittsburgh, PA; University of Manchester, Manchester, United Kingdom; Oregon Health & Science University, Portland, OR.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_174930DOI Listing
November 2017

Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.

Eur J Cancer 2017 09 7;82:171-183. Epub 2017 Jul 7.

Cancer Research UK Clinical Trials Unit, College of Medical and Dental Sciences, Robert Aitken Institute, University of Birmingham, Birmingham, B15 2TT, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.06.006DOI Listing
September 2017

Immunotherapy: Does adjuvant ipilimumab have little adverse effect on quality of life?

Nat Rev Clin Oncol 2017 07 25;14(7):395-396. Epub 2017 Apr 25.

Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK; and at the QIMR Berghofer Medical Research Institute, Royal Brisbane and Woman's Hospital, 300 Herston Road, Herston, Queensland 4029, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.60DOI Listing
July 2017

The role for chemotherapy in the modern management of melanoma.

Melanoma Manag 2017 May 19;4(2):125-136. Epub 2017 May 19.

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, M20 4BX, UK.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/mmt-2017-0003
Publisher Site
http://dx.doi.org/10.2217/mmt-2017-0003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094602PMC
May 2017

Integrating radiation therapy with emerging systemic therapies: Lessons from a patient with cerebral radionecrosis, spinal cord myelopathy, and radiation pneumonitis.

Pract Radiat Oncol 2016 Mar-Apr;6(2):110-3. Epub 2015 Oct 22.

University of Manchester, Manchester Cancer Research Centre, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, UK; School of Medicine, University of Queensland, Brisbane, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prro.2015.10.008DOI Listing
January 2017

Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma.

Am Soc Clin Oncol Educ Book 2016 ;35:e505-14

From the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; St. Luke's University Hospital, Temple University, Allentown, PA; University of Manchester, The Christie NHS Foundation Trust, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_159087DOI Listing
January 2017

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.

J Clin Oncol 2017 Jan 7;35(2):226-235. Epub 2016 Nov 7.

Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.67.9258
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.67.9258DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559888PMC
January 2017

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

J Clin Oncol 2016 11;34(31):3740-3748

Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, Grosshansdorf; Michael Thomas, Translational Lung Research Center Heidelberg, Thoraxklinik im Universitätsklinikum Heidelberg, Heidelberg, Germany; Alexander Luft, Leningrad Regional Clinical Hospital, Leningrad, Russia; Aleksandra Szczesna, Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy w Otwocku, Otwocku, Poland; Libor Havel, Hospital Na Bulovce, Prague, Czech Republic; Sang-We Kim, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Korea; Wallace Akerley, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Maria Catherine Pietanza, Memorial Sloan Kettering Cancer Center, New York, NY; Kathryn Gold, University of Texas MD Anderson Cancer Center, Houston, TX; Leora Horn, Vanderbilt-Ingram Cancer Center; David Spigel, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Anne Pieters, Teresa Kong Sanchez, and Justin Fairchild, Bristol-Myers Squibb, Princeton, NJ; Yi-long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong, People's Republic of China; Christoph Zielinski, Medical University of Vienna, Vienna, Austria; Enriqueta Felip, Vall d'Hebron University Hospital, Barcelona, Spain; Joachim Aerts, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Kazuhiko Nakagawa, Kinki University Hospital, Osaka, Japan; and Paul Lorigan, the Christie NHS Foundation Trust, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.67.6601
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.67.6601DOI Listing
November 2016

Hyponatraemia secondary to nivolumab-induced primary adrenal failure.

Endocrinol Diabetes Metab Case Rep 2016 1;2016. Epub 2016 Nov 1.

Departments of Medical Oncology , The Christie NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester , UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/EDM-16-0108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5097140PMC
November 2016

Sequential immunotherapy regimens-expect the unexpected.

Lancet Oncol 2016 07 4;17(7):854-855. Epub 2016 Jun 4.

Christie NHS Foundation Trust, Manchester M20 4BX UK; Institute of Cancer Sciences, University of Manchester, Manchester, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30198-XDOI Listing
July 2016

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.

Invest New Drugs 2016 06 9;34(3):290-9. Epub 2016 Mar 9.

Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Whitham Road, Sheffield, S10 2SJ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-016-0336-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859861PMC
June 2016

Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?

Drugs 2016 Jun;76(9):925-45

Istituto Nazionale Tumori Fondazione "G. Pascale", Via Mariano Semmola, 80131, Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-016-0588-xDOI Listing
June 2016

Survival of patients with advanced metastatic melanoma: The impact of novel therapies.

Eur J Cancer 2016 Jan 17;53:125-34. Epub 2015 Dec 17.

Center for Dermatooncology, Department of Dermatology, University Tuebingen, 72074 Tuebingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.09.013DOI Listing
January 2016

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.

Melanoma Res 2015 Oct;25(5):432-42

aDepartment of Oncology bCambridge Cancer Trials Centre, Cambridge Clinical Trials Unit - Cancer Theme, Cambridge University Hospitals NHS Foundation Trust, Cambridge cSouthampton Experimental Cancer Medicine Center, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton dDepartment of Medical Oncology, The Christie, Manchester eDepartment of Medicine, Royal Marsden NHS Foundation Trust, London fOxford NIHR Biomedical Research Centre, Oxford gDepartment of Medical Oncology, Mount Vernon Hospital, Northwood hDepartment of Medical Oncology, Velindre Cancer Centre, Cardiff iNorthern Centre for Cancer Care, Newcastle upon Tyne jDirectorate of Haematology and Oncology, Guy's and St. Thomas' NHS Foundation Trust, London kDepartment of Medical Oncology, Royal Wolverhampton Hospitals lDepartment of Medical Oncology, Royal Preston Hospital mClinical Oncology, Norfolk and Norwich University Hospital nDivision of Clinical Sciences, St George's Hospital Medical School, London oDepartment of Oncology, Castle Hill Hospital, Hull pSheffield Experimental Cancer Medicine Centre, University of Sheffield, Weston Park Hospital, Sheffield qClinical Oncology Department, Royal Cornwall Hospitals rSt. James's Institute of Oncology, St. James's University Hospital, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000185DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560270PMC
October 2015

PD-L1 expression as a potential predictive biomarker.

Lancet Oncol 2015 Oct;16(13):1285-7

Istituto Nazionale Tumori, Fondazione G Pascale, Napoli, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00307-1DOI Listing
October 2015

The place of PD-1 inhibitors in melanoma management.

Lancet Oncol 2015 Aug 23;16(8):873-4. Epub 2015 Jun 23.

Christie NHS Foundation Trust and University of Manchester, Manchester, M20 4BX, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00094-7DOI Listing
August 2015

Dabrafenib and its use in the treatment of metastatic melanoma.

Melanoma Manag 2015 Aug 10;2(3):199-208. Epub 2015 Aug 10.

Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt.15.21DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094610PMC
August 2015

Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR.

Nat Med 2015 Jul 1;21(7):741-50. Epub 2015 Jun 1.

1] Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain. [2] Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain. [3] Institucio Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.3863DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968631PMC
July 2015

Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.

Lung Cancer 2015 May 16;88(2):117-23. Epub 2015 Feb 16.

The Christie NHS Foundation Trust, Wilmslow Road, Manchester M21 4BX, United Kingdom; The University of Manchester, Oxford Road, Manchester M13 9PL, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.02.007DOI Listing
May 2015

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.

J Clin Oncol 2014 Dec 10;32(35):4012-9. Epub 2014 Nov 10.

Joachim von Pawel, Asklepios Fachkliniken München-Gauting, Gauting; Jörg Mezger, St Vincentius-Kliniken Karlsruhe, Karlsruhe; Martin Steins, Thoraxklinik am Universitätsklinikum, Heidelberg; Wolfgang Schütte, Krankenhaus Martha-Maria Halle-Dölau, Halle; Martin Reck, Krankenhaus Großhansdorf, Großhansdorf, Germany; Robert Jotte, Rocky Mountain Cancer Center, Denver, CO, and US Oncology, Houston, TX; David R. Spigel, Sarah Cannon Research Institute, Nashville, TN; Mary E.R. O'Brien, Royal Marsden National Health Service (NHS) Foundation Trust, Surrey; Paul Lorigan, Christie NHS Foundation Trust, Manchester, United Kingdom; Mark A. Socinski, University of Pittsburgh Medical Center, Pittsburgh, PA; Léon Bosquée, Centre Hospitalier Universitaire Sart-Tilman, Liège; Kristiaan Nackaerts, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium; Jeffrey Bubis, Cancer Specialists of North Florida, Jacksonville, FL; José M. Trigo, Hospital Universitario Virgen de la Victoria, Malaga; Manuel Domine, Fundación Jiménez Diaz, Universidad Autónoma de Madrid, Madrid, Spain; Philip Clingan, Southern Medical Day Care Centre, Wollongong, New South Wales, Australia; Frances A. Shepherd, University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Shaoyi Li and Markus F. Renschler, Celgene, Summit, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.5392DOI Listing
December 2014

The role of chemotherapy in the modern management of melanoma.

Melanoma Manag 2014 Nov 4;1(2):173-184. Epub 2014 Dec 4.

Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt.14.20DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094611PMC
November 2014

No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.

Mol Oncol 2014 Sep 15;8(6):1140-58. Epub 2014 Aug 15.

Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester, UK. Electronic address:

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1016/j.molonc.2014.07.027
Publisher Site
http://dx.doi.org/10.1016/j.molonc.2014.07.027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528622PMC
September 2014

Vemurafenib-induced nonautoimmune haemolytic anaemia.

Melanoma Res 2014 Aug;24(4):418-9

Department of aMedical Oncology bHematology, The Christie NHS Foundation Trust, Wilmslow Road, Withington, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000094DOI Listing
August 2014

High-risk cutaneous melanoma follow-up: time for more intensive surveillance?

Melanoma Manag 2014 Aug 5;1(1):7-10. Epub 2014 Sep 5.

Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/mmt.14.8
Publisher Site
http://dx.doi.org/10.2217/mmt.14.8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094701PMC
August 2014

Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma.

Melanoma Res 2014 Feb;24(1):40-6

aClinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research bThe Christie NHS Foundation Trust cSchool of Cancer and Enabling Sciences, Manchester Cancer Research Centre and Manchester Academic Health Sciences Centre, University of Manchester, Manchester dAstraZeneca Pharmaceuticals, Alderley Park, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000025DOI Listing
February 2014

Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence.

J Clin Oncol 2014 Jan 16;32(3):185-90. Epub 2013 Dec 16.

Miranda J. Payne, Katerina Argyropoulou, Cheng Han, Sandie Wellman, and Mark R. Middleton, National Institute for Health Research Biomedical Research Centre, Oxford University Hospitals National Health Service Trust, Oxford; Paul Lorigan, Christie Hospital, Manchester; James J. McAleer, Cancer Centre, Belfast City Hospital, Belfast, Northern Ireland; David Farrugia, Cheltenham Hospital, Cheltenham; Neville Davidson, Chelmsford Hospital, Chelmsford; Charles Kelly, Newcastle General Hospital, Newcastle upon Tyne; David Chao, Royal Free Hospital, Hampstead; and Ernest Marshall, Clatterbridge Centre for Oncology, Bebington, Wirral, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.8717DOI Listing
January 2014

Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma.

J Invest Dermatol 2013 Jun 6;133(6):1582-90. Epub 2012 Dec 6.

Clinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jid.2012.468DOI Listing
June 2013

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.

Cancer Chemother Pharmacol 2013 May 20;71(5):1191-9. Epub 2013 Feb 20.

Institute for Cancer Research, Paul O'Gorman Building, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2113-1DOI Listing
May 2013

Considerations in developing and delivering a nonpharmacological intervention for symptom management in lung cancer: the views of patients and informal caregivers.

J Pain Symptom Manage 2012 Dec 5;44(6):831-42. Epub 2012 Jun 5.

Academic Palliative and Supportive Care Studies Group, Division of Primary Care, University of Liverpool, Liverpool, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpainsymman.2011.12.274DOI Listing
December 2012

Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.

Expert Rev Anticancer Ther 2012 Nov;12(11):1437-48

The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.12.124DOI Listing
November 2012

Identifying melanomas in primary care: can we do better?

BMJ 2012 Jul 4;345:e4244. Epub 2012 Jul 4.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmj.e4244DOI Listing
July 2012

Management of small cell lung cancer: recent developments for optimal care.

Drugs 2012 Mar;72(4):471-90

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.

View Article

Download full-text PDF

Source
http://link.springer.com/10.2165/11597640-000000000-00000
Publisher Site
http://dx.doi.org/10.2165/11597640-000000000-00000DOI Listing
March 2012

Survival benefits from follow-up of patients with lung cancer: a systematic review and meta-analysis.

J Thorac Oncol 2011 Dec;6(12):1993-2004

School of Nursing, Midwifery and Social Work, Jean McFarlane Building, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e31822b01a1DOI Listing
December 2011

Lung cancer after treatment for breast cancer.

Lancet Oncol 2010 Dec 10;11(12):1184-92. Epub 2010 Jun 10.

Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(10)70056-5DOI Listing
December 2010

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma.

Clin Cancer Res 2010 Feb 19;16(3):1042-8. Epub 2010 Jan 19.

University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-2033DOI Listing
February 2010